{"version":"1.0","type":"link","title":"Insights Into Vepdegestrant (ARV-471): The First-in-Class Estrogen Receptor Proteolysis-Targeting Chimera Approaching Food and Drug Administration Approval for Breast Cancer.","author_name":"Tang C 외","author_url":"https://prs-insight.online/author/Tang%20C","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/78868","thumbnail_width":1200,"thumbnail_height":630}